Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Nemo Marjanovic
#474: OpenAI Launched GPT-5 In Pursuit Of Technical Leadership And Mass Adoption, & More
The diagnostics landscape is shifting, its success hinging not on a single breakthrough but on a new value chain with three drivers: scientific innovation that will create tests, commercial distribution, and data moats that learn from real-world evidence. The most durable franchises will control at least two of those value drivers. The recent licensing deal between Exact Sciences and Freenome for a colorectal cancer (CRC) screening test is a powerful illustration.
Pharmaceutical Superintelligence With Alex Zhavoronkov
In this episode of FYI, Chief Futurist, Brett Winton, and Analyst Nemo Marjanovic speak with Alex Zhavoronkov, founder and CEO of Insilico Medicine. Together, they explore the promise of artificial intelligence in transforming the drug discovery process—cutting years off timelines and dramatically reducing costs.
#469: Crypto’s First Step Into US Housing: From Wallets To Mortgages, & More
Skip to main content
AI Meets Biotech: The Future Of Protein Therapeutics With Mike Nally And Jason Silvers
In this episode of FYI – For Your Innovation, Brett Winton and ARK analyst Nemo Despot sit down with Generate Biomedicines CEO Mike Nally and CFO Jason Silvers to explore how generative AI is transforming the discovery and development of protein-based therapeutics.
Mapping The Brain: The Future Of Neuroscience With Dr. Jin Hyung Lee
In this episode of FYI - For Your Innovation, ARK’s Chief Futurist, Brett Winton, and Research Analyst Nemo Marjanovic, sit down with Dr. Jin Hyung Lee, a leading neuroscience researcher at Stanford University. Dr. Lee and her team are pioneering breakthroughs in understanding brain function—an essential step toward diagnosing and treating neurological disorders.
How Lila Is Redefining Scientific Discovery With Geoffrey von Maltzahn
In this episode of For Your Innovation, Brett Winton, along with ARK Invest Chief Investment Strategist, Charles Roberts, and Research Analyst, Nemo Marjanovic, sit down with Geoffrey von Maltzahn, CEO and founder of Lila Sciences and a general partner at Flagship Pioneering. Fresh out of stealth mode, Lila is pioneering the concept of scientific superintelligence—leveraging AI and automation to accelerate discovery across materials science, chemistry, and life sciences.
#455: Apple Is Delaying Apple Intelligence, & More
Apple has delayed the release of some of its most widely touted Apple Intelligence features until 2026 or later.1 Though the delay may be a surprise to seasoned Apple observers,2 disruptive technologies are challenging for incumbents—now including Apple—to incorporate.3 The characteristics that make AI interesting may not be consistent with Apple’s buttoned-up, optimized ecosystem. Though a one-year delay might sound insignificant, such a time-gap is dramatic and potentially deadly in the AI age.
Replacing Animal Testing: Organoids And AI With Thomas Hartung
In this episode of FYI, Brett Winton and Nemo Marjanovic sit down with Professor Thomas Hartung, MD-PhD, a leading expert in biomedical innovation at Johns Hopkins Bloomberg School of Public Health. They explore how human organoids—3D organ proxies—are revolutionizing drug discovery and toxicology testing by reducing reliance on animal models.
#447: Blue Origin’s New Glenn Reaches Orbit As SpaceX’s Starship Advances Toward Mars, & More
Biotech investors are witnessing a growing divergence between private and public markets, both in valuations and performance. Private investors are betting on long-term innovation, while public markets are focusing on short-term profitability. Will regulatory and economic shifts close that gap? In 2024, the private market in biotech bounced back with 96 megarounds (nine-figure financing) that approached the 106 funded in 2021.
The transformative potential of biotechnology and AI in healthcare
Advances in biotechnology and artificial intelligence (AI) are expanding scientists’ ability to discover new therapeutic targets and innovate new treatment modalities for more precise and effective interventions with fewer side effects.
#430: DeepMind’s New AI System, AlphaProteo, Should Accelerate The Discovery Of New Drugs, & More
Last week, Google’s DeepMind released AlphaProteo, a cutting-edge AI system that designs proteins which bind tightly to target molecules and could accelerate research in the development of drugs, diagnostics, and more. Proteins interact to regulate cellular processes.
#429: Single-Cell And Spatial Genomics Are Revolutionizing Cancer Prognostics And Treatment, & More
The integration of Large Language Models (LLMs) with digital wallets like Apple Pay, WeChat Pay, and Shop Pay could create “smart wallets”—powerful e-commerce aggregators that potentially would transform e-commerce. Integrating seamlessly with LLMs, digital wallets should be able to understand the intent behind consumer purchases, enabling them to offer consumers valuable insights with advanced search functionality.
#428: Robotaxis Continue To Scale, & More
We’re excited to see Baidu and Waymo scaling their robotaxi operations. Last week, Waymo confirmed that its sixth-generation robotaxi, developed by Geely’s Zeekr, will cut the number of onboard cameras from 29 to 13 and lidar sensors from five to four, compared to the hardware on Waymo’s Jaguar I-PACE.1 Although Waymo has not disclosed details, the cost of the new vehicle is likely to be much lower than the rumored ~$100,000+ for the current model2 —a critical step toward scaling operations.
#427: 10x Genomics Is Enabling Breakthroughs In AI-Driven Healthcare, & More
Sakana AI, a Tokyo-based AI research lab founded by former Google employees, recently released details on a new project called “The AI Scientist.” This “agentic”6 system is designed to automate the entire scientific process by combining the powerful capabilities of large language models, including language comprehension, planning, reasoning, and coding skills. AI Scientist follows the process illustrated below. Source: Sakana AI. For illustrative purposes only.
#426: Recursion And Exscientia Are Merging To Form An AI-Enabled Drug Discovery Powerhouse, & More
Informed by Wright’s Law, ARK’s research indicates that, with the exception of WWII, US electricity prices fell consistently from the late 1800s until 1974, as shown below. Source: ARK Investment Management LLC, 2024, based on data from U.S. Energy Information Administration 2024a, 2024b; Smil 2000; and Potter 2023.10 What happened in 1974?
#425: FDA Approval Of Guardant Health’s Shield™ Liquid Biopsy Could Transform Cancer Screening, & More
During the Bitcoin Nashville conference on July 27, Wyoming Senator Cynthia Lummis introduced the BITCOIN Act of 2024—Boosting Innovation, Technology, and Competitiveness Through Optimized Investment Nationwide Act of 2024—proposing a Bitcoin Purchase Program for a Strategic Bitcoin Reserve that could position the United States as a pioneer incorporating digital assets into its national reserves strategy.5 The bill proposes that the ~200,000 bitcoins confiscated by the US government after the...
#422: TempusAI Is Leading The Charge In AI-Driven Predictive and Personalized Medicine, & More
Last week, Tesla pushed its Cybercab announcement from August 8 to October, perhaps to give its design team time to complete work or to align the event with a software upgrade and the launch of a geography for its pilot ride-hail network. Tesla isn’t the first contender to tout a robotaxi-specific design. Waymo, Cruise and Zoox, for example, have revealed renderings without steering-wheels and prototypes supporting robotaxi operations without drivers.
#420: Big Data Aggregation Is Paving The Way For Precision Oncology, & More
Last week, Anthropic released Claude 3.5 Sonnet,6 the first of its new family of large language models . (LLMs). Claude 3.5 Sonnet sets new records for frontier foundation models on both general knowledge benchmarks like MMLU (Massive Multitask Language Understanding) and coding benchmarks like HumanEval, as shown below. On many benchmarks, it rivals or surpasses the performance of OpenAI's GPT-4o.
Unveiling Proteins: The Future Of Single-Cell Proteomics With Professor Nikolai Slavov
In this episode of FYI, Brett Winton, ARK's Chief Futurist, and Nemo Marjanovic, ARK's Multiomics Analyst, have an in-depth discussion with Professor Nikolai Slavov from Northeastern University. They explore the fascinating and complex world of multiomics, focusing on the importance of proteomics in understanding biological processes.
#417: Long-Read Sequencing And Single-Cell Genomics Are Shedding Important Light On Neuropsychiatric Disorders, & More
At the tail end of the ICO (Initial Coin Offering) bubble8 in 2018, Telegram launched9 the Telegram Open Network (TON) blockchain, selling its native token, TON, to raise10 $1.7 billion USD. In October 2019, the U.S. Securities and Exchange Commission (SEC) deemed11 the sale illegal and sued the company. In response, Telegram severed its relationship with the blockchain project. Nonetheless, popular with its users, the project continued as a community-led initiative called The Open Network.
#415: Google’s AlphaFold3 Could Revolutionize Drug Design, & More
During its Spring Update, OpenAI showcased GPT-4o, a natively multimodal model that spans text, voice, audio, and video with improved performance across most benchmarks. The new model will power an enhanced ChatGPT voice experience that is able to adapt its tone to different situations and facilitate use cases like real time translation. The more lifelike ChatGPT voice assistant allows users to interrupt and direct the model dynamically, setting a new standard for interactivity.
George Church: Decoding the Future of Genomics
On this episode of FYI, ARK Multiomics analyst Nemo Marjanovic sits down with Professor George Church, a renowned geneticist and entrepreneur from Harvard. They discuss the evolution of genomic sequencing technologies, the intersection of genomics and blockchain for privacy, and the fascinating potential of DNA for data storage.
The Power Of Fitness Wearables with Stanford’s Dr. Michael Snyder
On this episode of FYI, hosts Nemo Marjanovic and Charles Roberts speak with Professor Dr. Michael Snyder, a leading figure in genomics and personalized medicine. The discussion traverses Snyder's work in genomics, systems biology, and the utilization of wearables for health monitoring.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Nemo
Contact Nemo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack